Physician profile
Aric K Park
NPI 1871717140
$6,213.55
in general payments reported to CMS, 2019-2025
22 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what 89% of Facial Plastic Surgery providers received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $156 · 2021: $505 · 2022: $659 · 2023: $1,706 · 2024: $1,309 · 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,257 · Debt Forgiveness: $1,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,256.71 |
| Debt Forgiveness | $1,014.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Health Care Systems INC. | $1,014.32 | 2023 | |
| Integra Lifesciences Corporation | $854.50 | 2022-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Abbvie INC. | $711.69 | 2023-2025 | |
| Stryker Corporation | $615.59 | 2019-2025 | Clarifix, Scopis Ent |
| Galderma Laboratories, L.P. | $553.89 | 2019-2025 | Dysport |
| Aerin Medical INC. | $442.85 | 2021-2024 | |
| Allergan, INC. | $407.40 | 2019-2020 | |
| Musculoskeletal Transplant Foundation INC. | $262.58 | 2024 | |
| Axogen | $223.33 | 2023-2025 | Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector |
| Lilly USA, LLC | $184.37 | 2022-2025 | Ebglyss, Taltz |
| Baxter Healthcare | $173.43 | 2025 | Perclot, Artiss |
| Intersect Ent, INC. | $155.07 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $129.68 | 2020-2024 | |
| Janssen Biotech, INC. | $111.40 | 2021-2023 | Simponi, Simponi Aria, Stelara |
| Revance Therapeutics, INC. | $93.96 | 2024 | Daxxify |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $71.98 | 2021-2023 | Adbry |
| Merz North America, INC. | $57.24 | 2022-2024 | |
| Ucb, INC. | $49.15 | 2025 | Bimzelx |
| Celgene Corporation | $33.40 | 2019 | |
| Epi Health, LLC | $24.47 | 2019 | |
| Dusa Pharmaceuticals, INC. | $22.26 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aric Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.